3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Genitourinary
3
Tumor-Agnostic
1
Thoracic
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
14
Neoplasms
5
Adenocarcinoma of Lung
4
Carcinoma, Renal Cell
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Mesothelioma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Solitary Fibrous Tumor, Pleural
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Carboplatin
24
Pemetrexed
18
Cisplatin
17
Paclitaxel
14
pembrolizumab
13
Gemcitabine
8
osimertinib
7
durvalumab
6
Docetaxel
6
Nivolumab
5
Erlotinib Hydrochloride
5
130-nm albumin-bound paclitaxel
5
capmatinib
3
brigatinib
3
anlotinib
3
Gefitinib
3
Drug Therapy
3
vosaroxin
2
volociximab
2
sintilimab
2
pralsetinib
2
ensartinib
2
atezolizumab
2
aflibercept
2
Surgical Procedures, Operative
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Sorafenib
×
Thoracic
×
Clear all
NCT00863746
2015-01-19
MISSION
Bayer
Phase 3
Completed
703 enrolled
25 charts